Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
- PMID: 16798220
- DOI: 10.1016/j.athoracsur.2006.01.045
Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
Abstract
Background: Pulmonary resection after induction therapy is associated with high rates of pulmonary morbidity and mortality. However, the impact of induction therapy on the pulmonary toxicity and associated pulmonary complications has not been fully investigated in the setting of lung cancer surgery.
Methods: We assessed the 66 consecutive patients who underwent a pulmonary resection after induction therapy, 48 of whom received chemoradiotherapy and 18, chemotherapy alone. Results of pulmonary function before and after induction therapy were compared, and logistic regression analyses utilized to explore the risk factors of pulmonary morbidity.
Results: After induction therapy, forced expiratory volume in 1 second (FEV1) was increased significantly (from 2.28 +/- 0.61 L to 2.40 +/- 0.62 L; p < 0.05); however, percent vital capacity (%VC) and FEV1/FVC did not change significantly. The diffusing capacity of lung for carbon monoxide (D(LCO)) was decreased significantly by 21% (from 90.3% +/- 18.3% to 71.1% +/- 12.5%; p < 0.0005). Patients with respiratory complication showed lower predicted postoperative %FEV1 (49.5% +/- 11.1% versus 57.2% +/- 14.2%; p = 0.031) and predicted postoperative %Dlco (41.9% +/- 8.0% versus 55.4% +/- 10.1%; p < 0.0001) results than those without complications. Univariate and multivariate analyses revealed that predicted postoperative %D(LCO) alone was an independent factor to predict postoperative pulmonary morbidity.
Conclusions: For patients who undergo a pulmonary resection after induction therapy, predicted postoperative %D(LCO) is more important to predict pulmonary morbidity rather than static pulmonary function (predicted postoperative %VC or %FEV1). The decrease in D(LCO) is thought to reflect a limited gas exchange reserve, caused by the potential toxicity of chemotherapy or chemoradiotherapy. We believe that the impact of diffusion limitation after induction therapy should to be emphasized to decrease the pulmonary morbidity.
Similar articles
-
Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications.Ann Thorac Surg. 2009 Sep;88(3):930-5; discussion 935-6. doi: 10.1016/j.athoracsur.2009.06.013. Ann Thorac Surg. 2009. PMID: 19699923
-
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.Respiration. 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30. Respiration. 2014. PMID: 24192055 Clinical Trial.
-
Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer.J Cardiovasc Surg (Torino). 2002 Aug;43(4):539-44. J Cardiovasc Surg (Torino). 2002. PMID: 12124570
-
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085. Ann Thorac Surg. 2004. PMID: 15464470 Review.
-
Bronchial and arterial sleeve resection after induction therapy for lung cancer.Thorac Surg Clin. 2014 Nov;24(4):411-21. doi: 10.1016/j.thorsurg.2014.07.006. Epub 2014 Sep 11. Thorac Surg Clin. 2014. PMID: 25441134 Review.
Cited by
-
Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.Am J Respir Crit Care Med. 2008 Aug 1;178(3):225-32. doi: 10.1164/rccm.200801-090OC. Epub 2008 May 8. Am J Respir Crit Care Med. 2008. PMID: 18467511 Free PMC article.
-
Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective.Eur Respir Rev. 2024 Mar 20;33(171):230195. doi: 10.1183/16000617.0195-2023. Print 2024 Jan 31. Eur Respir Rev. 2024. PMID: 38508666 Free PMC article. Review.
-
Airway bacterial colonization in patients with non-small cell lung cancer and the alterations during the perioperative period.J Thorac Dis. 2014 Sep;6(9):1200-8. doi: 10.3978/j.issn.2072-1439.2014.07.07. J Thorac Dis. 2014. PMID: 25276361 Free PMC article.
-
Clinical pathway for thoracic surgery in the United States.J Thorac Dis. 2016 Feb;8(Suppl 1):S29-36. doi: 10.3978/j.issn.2072-1439.2015.11.21. J Thorac Dis. 2016. PMID: 26941967 Free PMC article. Review.
-
Comparison of pulmonary function changes between patients receiving neoadjuvant chemotherapy and chemoradiotherapy prior to minimally invasive esophagectomy: a randomized and controlled trial.Langenbecks Arch Surg. 2022 Nov;407(7):2673-2680. doi: 10.1007/s00423-022-02646-x. Epub 2022 Aug 25. Langenbecks Arch Surg. 2022. PMID: 36006505 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical